GlassScriptPhysician profile
Krishnaiyer Subramani
NPI 1295794105
$3,005.14
in general payments reported to CMS, 2019-2025
24 companies · $286 in 2025
The $286 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $172 · 2021: $446 · 2022: $464 · 2023: $900 · 2024: $490 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,577.21 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $755.86 | 2020-2024 | Xifaxan |
| Boston Scientific Corporation | $436.44 | 2023-2024 | Orise, Varithena Administration Pack, Wallflex Duodenal |
| Redhill Biopharma INC. | $244.11 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Takeda Pharmaceuticals U.S.A., INC. | $234.40 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $185.77 | 2021-2023 | Rebyota |
| Janssen Biotech, INC. | $178.37 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $130.68 | 2022-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $112.32 | 2024-2025 | Voquezna |
| Abbvie INC. | $111.00 | 2022-2025 | |
| Ardelyx, INC. | $107.91 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $103.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $101.15 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $41.52 | 2024-2025 | |
| Concordia Pharmaceuticals INC. | $33.02 | 2019 | |
| Daiichi Sankyo INC. | $28.87 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $27.99 | 2022-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $27.04 | 2022 | |
| Shield Therapeutics INC | $26.14 | 2023 | Accrufer |
| Shionogi INC | $24.05 | 2019 | |
| Evoke Pharma, INC. | $23.54 | 2020 | |
| Genzyme Corporation | $22.45 | 2023 | |
| Alfasigma USA, INC. | $22.04 | 2020 | |
| Horizon Therapeutics Plc | $14.69 | 2022 | |
| Allergan, INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnaiyer Subramani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.